JP2022549915A - ノッティン－免疫刺激剤複合体ならびに関連組成物および方法 - Google Patents

ノッティン－免疫刺激剤複合体ならびに関連組成物および方法 Download PDF

Info

Publication number
JP2022549915A
JP2022549915A JP2022519458A JP2022519458A JP2022549915A JP 2022549915 A JP2022549915 A JP 2022549915A JP 2022519458 A JP2022519458 A JP 2022519458A JP 2022519458 A JP2022519458 A JP 2022519458A JP 2022549915 A JP2022549915 A JP 2022549915A
Authority
JP
Japan
Prior art keywords
conjugate
knottin
peptide
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022519458A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021067261A5 (https=
JP2022549915A5 (https=
Inventor
イディト サジブ―バルフィ、
ロナルド レヴィ、
ケイトリン ミラー、
ジェニファー アール． コクラン、
キャロライン アール． ベルトッツィ、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2022549915A publication Critical patent/JP2022549915A/ja
Publication of JPWO2021067261A5 publication Critical patent/JPWO2021067261A5/ja
Publication of JP2022549915A5 publication Critical patent/JP2022549915A5/ja
Priority to JP2025138126A priority Critical patent/JP2026004279A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022519458A 2019-09-30 2020-09-29 ノッティン－免疫刺激剤複合体ならびに関連組成物および方法 Pending JP2022549915A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025138126A JP2026004279A (ja) 2019-09-30 2025-08-21 ノッティン－免疫刺激剤複合体ならびに関連組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962908305P 2019-09-30 2019-09-30
US62/908,305 2019-09-30
PCT/US2020/053258 WO2021067261A1 (en) 2019-09-30 2020-09-29 Knottin-immunostimulant conjugates and related compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025138126A Division JP2026004279A (ja) 2019-09-30 2025-08-21 ノッティン－免疫刺激剤複合体ならびに関連組成物および方法

Publications (3)

Publication Number Publication Date
JP2022549915A true JP2022549915A (ja) 2022-11-29
JPWO2021067261A5 JPWO2021067261A5 (https=) 2023-10-03
JP2022549915A5 JP2022549915A5 (https=) 2023-10-03

Family

ID=75337493

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022519458A Pending JP2022549915A (ja) 2019-09-30 2020-09-29 ノッティン－免疫刺激剤複合体ならびに関連組成物および方法
JP2025138126A Pending JP2026004279A (ja) 2019-09-30 2025-08-21 ノッティン－免疫刺激剤複合体ならびに関連組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025138126A Pending JP2026004279A (ja) 2019-09-30 2025-08-21 ノッティン－免疫刺激剤複合体ならびに関連組成物および方法

Country Status (8)

Country Link
US (1) US20220257785A1 (https=)
EP (1) EP4037709A4 (https=)
JP (2) JP2022549915A (https=)
KR (1) KR20220071225A (https=)
CN (1) CN114585382A (https=)
AU (1) AU2020357806A1 (https=)
CA (1) CA3156165A1 (https=)
WO (1) WO2021067261A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022552416A (ja) * 2019-10-16 2022-12-15 マサチューセッツ インスティテュート オブ テクノロジー ブラシプロドラッグおよびその使用
US12414997B2 (en) 2018-04-13 2025-09-16 Massachusetts Institute Of Technology Brush prodrugs and uses thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
CN113891731A (zh) * 2019-05-22 2022-01-04 小利兰·斯坦福大学理事会 药物缀合物及其使用方法
WO2025103490A1 (en) * 2023-11-16 2025-05-22 Beijing Changping Laboratory N-oxide immune agonists activation by radiotherapy
WO2025193946A2 (en) * 2024-03-14 2025-09-18 Genentech, Inc. Peptides binding lrrc15 and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170304342A1 (en) * 2016-03-15 2017-10-26 The Board Of Trustees Of The Leland Stanford Junior University Knottin-drug conjugates and methods of using the same
US20190054145A1 (en) * 2016-02-12 2019-02-21 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2638173B1 (en) * 2010-11-08 2019-06-19 The Board of Trustees of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
WO2014063012A1 (en) * 2012-10-19 2014-04-24 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
WO2014201245A1 (en) * 2013-06-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
JP6800141B2 (ja) * 2014-08-12 2020-12-16 マサチューセッツ インスティテュート オブ テクノロジー Ｉｌ−２およびインテグリン結合性ｆｃ融合タンパク質による相乗的な腫瘍処置
MX2019012295A (es) * 2017-04-14 2020-02-07 Tollnine Inc Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
CN113891731A (zh) * 2019-05-22 2022-01-04 小利兰·斯坦福大学理事会 药物缀合物及其使用方法
US20230211001A1 (en) * 2020-07-30 2023-07-06 The Board Of Trustees Of The Leland Stanford Junior University Lysosomal Targeting Molecules Comprising Knottin Peptides And Related Compositions And Methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190054145A1 (en) * 2016-02-12 2019-02-21 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccine
US20170304342A1 (en) * 2016-03-15 2017-10-26 The Board Of Trustees Of The Leland Stanford Junior University Knottin-drug conjugates and methods of using the same

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12414997B2 (en) 2018-04-13 2025-09-16 Massachusetts Institute Of Technology Brush prodrugs and uses thereof
JP2022552416A (ja) * 2019-10-16 2022-12-15 マサチューセッツ インスティテュート オブ テクノロジー ブラシプロドラッグおよびその使用
US12478683B2 (en) 2019-10-16 2025-11-25 Massachusetts Institute Of Technology Brush prodrugs and uses thereof
JP7815112B2 (ja) 2019-10-16 2026-02-17 マサチューセッツ インスティテュート オブ テクノロジー ブラシプロドラッグおよびその使用

Also Published As

Publication number Publication date
WO2021067261A1 (en) 2021-04-08
US20220257785A1 (en) 2022-08-18
KR20220071225A (ko) 2022-05-31
CN114585382A (zh) 2022-06-03
CA3156165A1 (en) 2021-04-08
JP2026004279A (ja) 2026-01-14
AU2020357806A1 (en) 2022-05-26
EP4037709A1 (en) 2022-08-10
EP4037709A4 (en) 2023-10-11

Similar Documents

Publication Publication Date Title
JP2022549915A (ja) ノッティン－免疫刺激剤複合体ならびに関連組成物および方法
JP7564143B2 (ja) Ｘｔｅｎ共役組成物およびそれを製造する方法
JP7417432B2 (ja) 新規リンカー、その製造方法およびその応用
US20240309058A1 (en) Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
EP3893913B1 (en) Transferrin receptor targeting peptides
US20250326866A1 (en) Transferrin receptor targeting peptide oligonucleotide complexes and methods of use thereof
US10765625B2 (en) Knottin-drug conjugates and methods of using the same
JP2021130672A (ja) Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド
US12303555B2 (en) Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages
Mishra et al. Cell-penetrating peptides and peptide nucleic acid-coupled MRI contrast agents: evaluation of cellular delivery and target binding
WO2022125673A1 (en) Cell-penetrating peptides and peptide complexes and methods of use
WO2011071279A2 (ko) Bpb-기반 카르고 운반 시스템
Forner et al. Peptide-based multiepitopic vaccine platforms via click reactions
CN115811990B (zh) 新型核仁素结合肽及其应用
Khandia et al. Tumor homing peptides: Promising futuristic hope for cancer therapy
Xu et al. CD44‐Assisted Transcytosable Chimeras for Extracellular Protein Depletion in Deep Tumors
Bánóczi et al. Amino acid and peptide bioconjugates
Novak et al. N-terminal cysteine as minimalistic handle for dual, site-selective bioconjugation: application to an anti-HER2 affibody reveals synergy of two conjugated drugs
US20200390898A1 (en) Knottin-drug conjugates and methods of using the same
CN121313861A (zh) 基于多肽改性的核酸适体偶联药物
JP2025524355A (ja) ユビキチン高親和性環状ペプチドおよびその使用方法
Rana et al. Peptide Biomarkers and Assay Development
CN117836316A (zh) 能够抑制myc驱动的转录的共价蛋白质二聚体的合成
HARISH IDENTIFICATION OF MAMMARY TUMOR HOMING PEPTIDES AND DEVELOPMENT OF TARGETED GENE DELIVERY VEHICLE

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250821